Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Statin meta-analysis

This article was originally published in The Tan Sheet

Executive Summary

Statin therapy "can reduce the five-year incidence of major coronary events and stroke by about one fifth per mmol/L reduction in LDL cholesterol," according to a prospective meta-analysis published online by The Lancet Sept. 27. The study analyzed the results of 14 randomized trials such as AFCAPS, ALERT and ASCOT, and involved a total of more than 90,000 patients. Among the deaths caused by coronary heart disease, 1,548 were in the statin treatment group while 1,960 were in the control group. The results "are consistent with there being an approximately linear relationship between the absolute reductions in LDL cholesterol achieved in these trials and the proportional reductions in the incidence of coronary and other major vascular events," the Cholesterol Treatment Trialists' Collaboration concludes. "Statin therapy produced a clear reduction in all-cause mortality," they add...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel